The Best Things in Life are NOT Free: Assessing the Intricacies of Deal-Related IP Valuation

November 30, 2018 9:00am

Greg Bell
Group Vice President and Life Sciences Practice Leader
Charles River Associates (Boston, MA)

Geoffrey Taylor Gibbs
Deputy General Counsel, Business, Finance and Innovation
University of California, Office of the President (Oakland, CA)

Forrester J. Liddle Ph.D., J.D.
Director of Intellectual Property
Jounce Therapeutics (Cambridge, MA)


Brenda Jarrell, Ph.D.
Co-Chair of Intellectual Property and Life Sciences
Choate, Hall & Stewart LLP (Boston, MA)

  • Framing the deal: Building a perspective on goals and risks from both sides of the table
  • Evaluating and differentiating between critical and manageable risks
  • Assessing valuation models and adjusting for value drivers such as: regulatory exclusivities, pending legislation, follow-on development, and competing IP
  • Adjusting valuation for the results of the diligence analysis: opportunity and risk
  • Building the deal to maximize value